GuidelineJCO global oncology2021
Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline.
Guideline in JCO global oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Fertility-sparing surgery upon reproductive and oncologic results in ovarian cancer patients stage I (FIGO): a systematic review.Archives of gynecology and obstetrics · 2025Pooled it
- Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancerRevista colombiana de obstetricia y ginecologia · 2024Guideline
- Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.JCO global oncology · 2024Guideline
- Guideline
- Cropsi study: Efficacy and safety of cryotherapy and cryocompression in the prevention of chemotherapy-induced peripheral neuropathy in patients with breast and gynecological cancer-A prospective, randomized trial.Breast (Edinburgh, Scotland) · 2024Trial
- HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge.Gynecologic oncology reports · 2026Article
- Ovarian cancer.Nature reviews. Disease primers · 2026Review
- Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study using inverse probability of treatment weighting.World journal of surgical oncology · 2026Article
- Management of epithelial ovarian cancer in sub-Saharan Africa: a survey of practicing physicians.Ecancermedicalscience · 2026Article
- Laparoscopy in the Surgical Management of Gynecological Cancer: A Comprehensive Update.Journal of clinical medicine · 2025Review
- Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients.The oncologist · 2025Article
- Tackling disease-related malnutrition in resource-limited settings: An international position paper based on expert consensus.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025Article
- CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations.Journal of clinical medicine · 2025Review
- Article
- Fertility Sparing Medical Management Options in Gynecologic Cancers.Current treatment options in oncology · 2025Review
- Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens.Cancers · 2025Review
- Pegylated liposomal doxorubicin in partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer: a prospective study.The oncologist · 2025Article
- Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer.Open medicine (Warsaw, Poland) · 2025Article
- Does maximal effort cytoreductive surgery after 6-cycles of chemotherapy play a role in the management of advanced ovarian cancer?Archives of gynecology and obstetrics · 2024Article
- Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo provide expert guidance to clinicians and policymakers in three resource-constrained settings on diagnosis and staging of adult women with ovarian masses and treatment of patients with epithelial ovarian (including fallopian tube and primary peritoneal) cancer.
methodsA multidisciplinary, multinational ASCO Expert Panel reviewed existing guidelines, conducted a modified ADAPTE process, and conducted a formal consensus process with additional experts.
resultsExisting sets of guidelines from eight guideline developers were found and reviewed for resource-constrained settings; adapted recommendations from nine guidelines form the evidence base, informing two rounds of formal consensus; and all recommendations received ≥ 75% agreement. RECOMMENDATIONS: Evaluation of adult symptomatic women in all settings includes symptom assessment, family history, and ultrasound and cancer antigen 125 serum tumor marker levels where feasible. In limited and enhanced settings, additional imaging may be requested. Diagnosis, staging, and/or treatment involves surgery. Presurgical workup of every suspected ovarian cancer requires a metastatic workup. Only trained clinicians with logistical support should perform surgical staging; treatment requires histologic confirmation; surgical goal is staging disease and performing complete cytoreduction to no gross residual disease. In first-line therapy, platinum-based chemotherapy is recommended; in advanced stages, patients may receive neoadjuvant chemotherapy. After neoadjuvant chemotherapy, all patients should be evaluated for interval debulking surgery. Targeted therapy is not recommended in basic or limited settings. Specialized interventions are resource-dependent, for example, laparoscopy, fertility-sparing surgery, genetic testing, and targeted therapy. Multidisciplinary cancer care and palliative care should be offered.Additional information can be found at www.asco.org/resource-stratified-guidelines. It is ASCO's view that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.